Professor TSE Hung Fat

Prof HF Tse

Department Chairperson
Chief of Service (Medicine), Queen Mary Hospital
William MW Mong Professor in Cardiology
Chair of Cardiovascular Medicine
Chief of Cardiology Division
Specialist in Cardiology

  • MBBS(HK), MD(HK), PhD(HK), MRCP(UK), FRCP(Edinburgh, Glasgow, Lond), FHKCP, FHKAM(Medicine)
Professor Hung-Fat Tse is Chairperson of the Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, the University of Hong Kong. He is also Chief of the Cardiology Division, Honorary Consultant and Chief of Service of the Department of Medicine at Queen Mary Hospital.

Professor Tse received his medical degree from the University of Hong Kong, Hong Kong. He completed his postgraduate training in Internal Medicine and Cardiology in the Department of Medicine, Queen Mary Hospital, University of Hong Kong, and his cardiac-electrophysiology training fellowship at the University of Michigan, USA.

Professor Tse is an international expert in cardiac pacing and electrophysiology, and cardiovascular regenerative medicine. He has significantly contributed to the understanding of the mechanisms as well as development of novel therapies for treatment of heart rhythm disorder. In addition, Professor Tse is at the forefront of applying stem cells in cardiovascular regenerative medicine. His research center and basic laboratory together with the Sun Chieh Yeh Cardiovascular Research and Training Laboratory (for large animal research) are dedicated to the training and development of novel device and biological therapies for cardiovascular diseases. Prof. Tse has published over 520 original scientific reports in international scientific journals, including New England Journal of Medicine, Nature Medicine, Lancet, Cell Stem Cell, Circulation, Blood, Journal of American College of Cardiology, Archives of Internal Medicine, American Journal of Medicine, European Heart Journal and Stem Cell.

Professor Tse's current projects include:
  • Basic and clinical cardiac electrophysiology;
  • Novel non-pharmacological therapies, such as medical devices and gene-based approaches for cardiac arrhythmias;
  • Non-invasive assessment of cardiovascular system, such as vascular ultrasound, CT scan and MRI; and
  • Cardiovascular regenerative medicine using gene-based and cell-based, including adult, embryonic and induced pluripotent stem cells.

Selected Publications
  1. Lau CP, Siu CW, Tse HF. The future of implantable devices for cardiac rhythm management. Circulation 2014;129:811-22.
  2. Yiu KH, Wong A, Pu L, Chiang R, Sit KY, Chan D, Lee HY, Lam YM, Chen Y, Siu CW, Lau CP, Au WK, Tse HF. Prognostic value of preoperative right ventricular geometry and tricuspid valve tethering area in patients undergoing tricuspid annuloplasty. Circulation 2014;129:87-92.
  3. Lau CP, Tachapong N, Wang CC, Wang JF, Abe H, Kong CW, Liew R, Shin DG, Padeletti L, Kim YH, Omar R, Jirarojanakorn K, Kim YM, Chen MC, Sriratanasathavorn C, Munawar M, Kam R, Chen JY, Cho YK, Li YG, Wu SL, Bailleul C, Tse HF, for SAFE Study Prospective Randomized Study to Assess the Efficacy of Site and Rate of Atrial Pacing on Long-term Progression of Atrial Fibrillation in Sick Sinus Syndrome- Septal Pacing for Atrial Fibrillation Suppression Evaluation (SAFE) study. Circulation 2013;128:687-93.
  4. Tse HF, Ho JC, Buter AW, Lee YK, Choi SW, Ng KM, Siu CW, Simpson MA, Lai WH, Chan YC, Zhang J, Lay KW, Esteban MA, Colman A, Sham PC. Patient-specific induced pluripotent stem cells derived cardiomyocytes recapitulates the pathogenic phenotypes of dilated cardiomyopathy due to a novel desmin gene mutation identified by whole exome sequencing. Hum Mol Genet 2013;22:1395-1403.
  5. Siu CW, Wong MP, Ho CM, Lam CL, Tse HF. Fatal lung toxic effects related to dronedarone. Arch Intern Med. 2012;172:516-7.
  6. Lip GY, Tse HF, Lane DA. Management of atrial fibrillation. Lancet 2012 18;379:648-61.
  7. Zhang J, Lian Q, Zhu G, Zhou F, Sui L, Tan C, Abdul Mutalif R, Navasankari R, Zhang Y, Tse HF, Stewart CL, Colman A. A human iPSC model of Hutchinson Gilford Progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell. 2010;8:31-45.
  8. Lian Q, Zhang Y, Zhang J, Zhang HK, Wu X, Zhang Y, Lam FY, Kang S, Xia JC, Lai WH, Au KW, Chow YY, Siu CW, Lee CN, Tse HF. Functional mesenchymal stem cells derived from human induced pluripotent stem cells attenuate limb ischemia in mice. Circulation 2010;121:1113-23.
  9. Chan YH, Lau KK, Yiu KH, Li SW, Chan HT, Fong YT, Tam S, Lau CP, Tse HF. Reduction of C-Reactive protein with isoflavone supplement reverses endothelial dysfunction in patients with ischaemic stroke. Eur Heart J 2008;29:2800-2807.
  10. Tse HF, Thambar S, Kwong YL, Rowlings P, Bellamy G, McCrohon J, Thomas P. Bastian B, Chan JKF, Lo G, Ho CL, Chan WS, Kwong RY, Parker A, Hauser T, Chan J, Fong YT, Lau CP. Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial).Eur Heart J. 2007; 28: 2998-3005.
  11. Lip GY, Tse HF. Management of atrial fibrillation. Lancet 2007;370:604-18.
  12. Tse HF, Xue T, Lau CP, Siu CW, Wang K, Zhang QY, Tomaselli GF, Akar FG, Li RA. Bioartificial sinus node constructed via in vivo gene transfer of an engineered pacemaker HCN channel reduces the dependence on electronic pacemaker in a sick sinus syndrome model. Circulation. 2006; 114: 1000-11.
  13. Siu CW, Au WY, Yung C, Kumana CR, Lau CP, Kwong YL, Tse HF. Effects of oral arsenic trioxide therapy on QT intervals: implications on long-term cardiac safety. Blood. 2006; 108: 103-6.
  14. Tse HF, Siu CW, Lee KLF, Fan K, Chan HW, Tang MO, Tsang V, Lee SWL, Lau CP. The incremental benefit of rate-adaptive pacing on exercise performance during cardiac resynchronization therapy. J Am Coll Cardiol. 2005; 46: 2292-97.
  15. Tse HF, Kwong YL, Lo G, Ho CL, Chan JKF, Yeung DW, Lau CP. Angiogenesis in ischemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet. 2003; 361: 47-9.

  • Sir Patrick Manson Gold Medal
  • Outstanding Young Researcher Award, HKU, Distinguished Research Paper Award for Young Clinicians from the Hong Kong College of Physicians
  • Late Breaking Clinical Trial, American College of Cardiology Meeting 2006; Ground-breaking Paper of 2006, 
  • American Heart Association 2007
  • Outstanding Researcher Award, HKU
  • Elite Reviewer 2009 for The Journal of the American College of Cardiology.
  • Sir David Todd Lecture for The Hong Kong College of Physicians 2010: “New Era of Regenerative Medicine for Cardiovascular Diseases”.
  • Late-breaking Clinical Trial in Special Clinical Session in American Heart Association Annual Scientific Meeting 2012: “Study Prospective Randomized Study to Assess the Efficacy of Site and Rate of Atrial Pacing on Long-term Progression of Atrial Fibrillation in Sick Sinus Syndrome- Septal Pacing for Atrial Fibrillation Suppression Evaluation (SAFE) study”
  • BMA Medical Book Awards 2012- Highly Commended in Cardiology
  • Late-breaking Clinical Trial in Heart Rhythm Society Annual Scientific Meeting 2014: Thoracic Spinal Cord Stimulation for Heart Failure as a Restorative Treatment (SCS HEART Study): First-in-man Experience

Grant Record
  1. 2012 NSFC/RGC Joint Research Grant (N-HKU 730/12)- Targeted gene correction and disease modeling using Wilson's disease induced pluripotent stem cells (Amount HK$1,027.619)
  2. 2012 Innovation and Technology Support Programme (Tier 3) (ITS/303/12) Viral-Vector Integration-Free Human Induced Pluripotent Stem Cells Platform Derived from Urine Samples for Disease Diagnosis and Drug Screening (Amount HK$ 993,031)
  3. 2012 Health and Medical Research Fund-Full Grant (10111531): Mendelian randomization to causally infer the impact of life-long vitamin D deficiency on Cardiovascular disease and death: implications for community-based cardiovascular prevention (Amount HK$999,000)
  4. 2013 General Research Fund (HKU780013M): Effects of Catheter-based Splanchnic Denervation on Blood Pressure Control and Left Ventricular Remodeling in Porcine Model of Hypertensive Cardiomyopathy (Amount HK$ 1,039,239)
  5.  2013 Major National Scientific Research Plan (973 Program, No. 2014CB965100),重大科学研究计划: 人胚胎干细胞衍生细胞治疗心肌梗死后心力衰竭的关键科学问题研究 (Amount CNY 3,960,000).
  6. 2014 General Research Fund (HKU17121014M): Lower Thoracic Spinal Cord Stimulation for Treatment of Heart Failure with Preserved Ejection Fraction: Insight from a Porcine Model of Hypertensive Cardiomyopathy (Amount HK$ 865,890)
  7. 2014 Innovation and Technology Support Programme (Tier 3)(ITS/087/14): Development of Wireless Powered Miniature Pacing Devices for Cardiac Rhythm Management (Amount HK$ 1,399,993)
  8. 2016 CAS - Croucher Funding Scheme for Joint Laboratories: Discovery of New Approaches for Treating Hyperlipidemia Using an Induced Pluripotent Stem Cell (iPSC)-Based Platform (Amount HK$ 1,000,000)

Key Offices
  • Academic Chief, Cardiology Division, The University of Hong Kong, Queen Mary Hospital, Hong Kong
  • Deputy Director, Research Center of the Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, the University of Hong Kong.
  • Honorary Consultant, Queen Mary Hospital/Tung Wah Hospital/ Ruttonjee Hospital/Kwong Wah Hospital. Hospital Authority, Hong Kong,
  • Member, Innovation & Technology Support Programme Assessment Panel on Biotechnology, Innovation and Technology Fund, HKSAR
  • Member, Hong Kong Research Grants Council (RGC) Assessment Panel on Joint Research Schemes (JRS) in Biology & Medicine field.
  • Member, Panel for the Health and Medical Research Fund (HMRF) for HKSAR Government
  • "Honorary Principle Investigator", Guangzhou Institute of Biomedicine and Health Chinese Academy of Sciences (GIBH), China
  • Co-director, Hong Kong-Guangdong Joint Laboratory on Stem Cell and Regenerative Medicine
  • Principle Investigators, Shenzhen Institutes of Research and Innovation, University of Hong Kong, China